loading page

Population pharmacokinetics of gabapentin in patients with neuropathic pain: the role of glycaemic control
  • +5
  • Ana Carolina Costa,
  • Jhohann Richard Benzi,
  • Priscila Yamamoto,
  • Maria Cristina Foss-Freitas,
  • Francisco José de Paula,
  • Cleslei Zanelli,
  • Gabriela Lauretti,
  • Natalia de Moraes
Ana Carolina Costa
Universidade de São Paulo Faculdade de Ciências Farmacêuticas de Ribeirão Preto
Author Profile
Jhohann Richard Benzi
Universidade de Sao Paulo Faculdade de Ciencias Farmaceuticas de Ribeirao Preto
Author Profile
Priscila Yamamoto
Universidade de Sao Paulo Faculdade de Ciencias Farmaceuticas de Ribeirao Preto
Author Profile
Maria Cristina Foss-Freitas
Universidade de São Paulo Faculdade de Medicina de Ribeirão Preto
Author Profile
Francisco José de Paula
Universidade de São Paulo Faculdade de Medicina de Ribeirão Preto
Author Profile
Cleslei Zanelli
Universidade Estadual Paulista Júlio de Mesquita Filho Câmpus de Araraquara Faculdade de Ciências Farmacêuticas
Author Profile
Gabriela Lauretti
Universidade de São Paulo Faculdade de Medicina de Ribeirão Preto
Author Profile
Natalia de Moraes
Universidade Estadual Paulista Julio de Mesquita Filho Faculdade de Ciencias Farmaceuticas Campus de Araraquara
Author Profile

Abstract

Aims: Gabapentin (GBP) is an α2-δ ligand drug widely used to treat neuropathic pain, especially diabetic neuropathy. The drug presents a saturable absorption in therapeutic doses and it is mainly eliminated unchanged in the urine. GBP excretion has been suggested to be dependent on glomerular filtration rate and active transport by renal drug carriers. Our objective was to evaluate the role of diabetes and glycaemic control on GBP pharmacokinetics using a population pharmacokinetic modelling approach. Methods: A clinical trial was conducted in participants with neuropathic pain of intensity ≥ 4 evaluated by visual analogue scale (VAS) (n=29), due to lumbar or cervical disc herniation or due to diabetic neuropathy. All participants were treated with a single oral dose of 300 mg GBP. Blood samples were collected up to 24 hours after GBP administration. A population pharmacokinetic analysis was conducted to evaluate the inter-individual variability considering as potential covariates weight, height, body mass index (BMI), sex, biomarkers of renal function and diabetes, and genotypes for the main genetic polymorphisms of SLC22A2 and SLC22A4, the genes encoding the transporters for organic cations OCT2 and OCTN1. Results: Population estimates for lag time, first-order absorption rate, total clearance and apparent volume of distribution at steady state were 0.32 h, 1.13 h-1, 14.7 L/h and 140 L, respectively. The total plasma clearance of GBP is affected by the estimated glomerular filtration rate and the volume of distribution increases with higher glycaemic levels. Conclusion: GBP population pharmacokinetics was affected by renal function and glycaemic control.